(Albany, US), October 20, 2026 – DelveInsight’s ‘Chronic Lower Back Pain Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of Chronic Lower Back Pain (CLBP), historical and forecasted epidemiology, as well as the Chronic Lower Back Pain market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Explore the intricate details of the Chronic Lower Back Pain Market Report @ Chronic Lower Back Pain Treatment Market Size
Key Takeaways from the Chronic Lower Back Pain Market Report
According to DelveInsight’s analysis, the Chronic Lower Back Pain treatment market size in the 7MM was ~USD 9,700 million in 2025, and it is projected to grow at a CAGR of ~5.4% during 2026-2036.
Among the 7MM, the United States accounted for the largest Chronic Lower Back Pain market size, i.e., ~USD 6,600 million in 2025.
The prevalent cases of CLBP in the 7MM were 148 million in 2025, rising at a CAGR of 0.8% during the study period, with the US accounting for ~50% (~76 million) of total prevalent cases.
In 2025, opioids accounted for approximately 30% of CLBP treatment use in the US, reflecting continued reliance on opioid analgesics for persistent or refractory pain despite increasing efforts to shift toward non-opioid and non-pharmacological alternatives.
Moderate CLBP represents the largest diagnosed subgroup, followed by mild CLBP, while severe CLBP, despite being the smallest segment, accounts for substantially higher healthcare utilization and intensive treatment.
The cell and gene therapy market in CLBP is an emerging segment focused on single-dose, potentially durable treatments that aim to promote disc regeneration, tissue repair, neuroprotection, and disease modification, with candidates such as rebonuputemcel (IDCT), rexlemestrocel-L, BRTX-100, olastrocel, KLS-2031, and others.
Among patients with moderate-to-severe CLBP, a clinically significant subgroup presents with Modic Type 1 changes, an inflammatory vertebral endplate phenotype associated with persistent pain and poorer outcomes, representing an emerging therapeutic target for investigational therapies such as PP353 (micronized linezolid).
The leading Chronic Lower Back Pain Companies include Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, Camurus, Scilex Holding, Mesoblast Limited, AnGes MG, Kolon Life Science, DiscGenics, VERTANICAL, and others.
Promising Chronic Lower Back Pain Therapies include VER-01 (EXILBY), Oxycodone ER abuse-deterrent (XTAMPZA ER), Buprenorphine Buccal Film (BELBUCA), SEMDEXA (SP-102), Retatrutide (LY3437943), Vicatertide (SB-01), Rebonuputemcel (IDCT), Rexlemestrocel-L (MPC-06-ID), and others.
Get a Free sample for the Chronic Lower Back Pain Market Forecast, Size & Share Analysis Report @ Chronic Lower Back Pain Therapeutics Market
Chronic Lower Back Pain Overview
Chronic low back pain is defined as pain localized to the lower back that persists for 12 weeks or longer, often continuing beyond the expected period of tissue healing. It is one of the leading causes of disability worldwide and is associated with significant physical, psychological, and socioeconomic burden, particularly among older adults. CLBP may arise from degenerative spinal disorders, mechanical abnormalities, nerve compression, or other underlying conditions, although a specific cause is often difficult to identify. Diagnosis is primarily based on a detailed medical history and physical examination to differentiate mechanical from non-mechanical causes, with imaging modalities such as X-ray, magnetic resonance imaging (MRI), or computed tomography (CT) reserved for patients with persistent symptoms, neurological deficits, or suspected serious underlying pathology.
Chronic Lower Back Pain Epidemiology Segmentation in the 7MM
Chronic Lower Back Pain Prevalent Cases
Chronic Lower Back Pain Cases by Etiology (Specific vs. Non-Specific)
Chronic Lower Back Pain Associated with Degenerative Disc Disease and Lumbosacral Radiculopathy
Chronic Lower Back Pain Cases by Disease Severity (Mild, Moderate, and Severe)
Chronic Lower Back Pain Cases by Gender
Chronic Lower Back Pain Cases by Age-group
Treated Mild and Moderate-to-Severe CLBP Cases
Download the report to understand which factors are driving Chronic Lower Back Pain Epidemiology trends @ Chronic Lower Back Pain Prevalence
Chronic Lower Back Pain Epidemiology Key Findings
The prevalent cases of CLBP in the 7MM were 148 million in 2025, and this number is expected to rise by 2036, driven primarily by population aging, increasing burden of degenerative spinal disorders, sedentary lifestyles, and rising obesity rates, along with improved disease recognition and greater healthcare utilization.
Among the 7MM, the US accounted for ~50% (~76 million) of total prevalent CLBP cases in 2025; these cases are expected to increase throughout the forecast period.
DDD is the leading cause of CLBP, driven by age-related spinal degeneration and cumulative mechanical stress.
In the US, CLBP severity was predominantly moderate (~50%), followed by mild (~30%) and severe (~20%).
Moderate-to-severe CLBP had a higher treatment rate in the United States, with ~32 million treated cases in 2025, compared with ~6 million treated cases for mild CLBP.
In the United States, among age-specific prevalent CLBP cases, patients aged 70 years and above accounted for 22 million cases, followed by those aged 50–59 in 2025, with both segments expected to increase by 2036.
Approved Therapies for Chronic Lower Back Pain
Oxycodone ER abuse-deterrent (XTAMPZA ER): Collegium Pharmaceutical
Oxycodone ER is Collegium’s first product utilizing the DETERx technology platform. Oxycodone, a Schedule II opioid, is an abuse-deterrent, extended-release, oral formulation designed to deter abuse and misuse (e.g., crushing, chewing, heating, and injecting). It is approved in the US (2016) and is protected by 12 issued US patents, with the remaining patents projected to expire in 2030 and 2036.
Buprenorphine Buccal Film (BELBUCA): Collegium Pharmaceutical
BELBUCA is a mu-opioid receptor partial agonist and a potent analgesic, approved in the US in 2015 for managing severe chronic pain requiring around-the-clock, long-term opioid therapy when alternative treatments are inadequate.
VER-01 (EXILBY): VERTANICAL
VER-01 (EXILBY) is a first-in-class non-opioid treatment for CLBP, a standardized full-spectrum extract derived from the Cannabis sativa strain DKJ127 L., with a defined mixture of cannabinoids, terpenes, and other bioactive compounds selected for their potential relevance in pain modulation and associated symptoms.
Chronic Lower Back Pain Pipeline Analysis
Rexlemestrocel-L (MPC-06-ID): Mesoblast and Grünenthal
Rexlemestrocel-L is positioned as a potentially first-in-class, disease-modifying cell therapy for moderate-to-severe CLBP associated with DDD in patients who remain symptomatic despite conservative treatment. Unlike conventional symptomatic therapies, it targets underlying disc pathology and is administered as a single intradiscal injection. Phase III data demonstrated sustained pain reduction for up to 36 months, particularly in patients with shorter disease duration, and 85% of surveyed pain specialists indicated they would likely recommend it based on clinical outcomes. It is in Phase III of clinical development.
Rebonuputemcel (IDCT): DiscGenics
Rebonuputemcel (IDCT) is a potentially first-in-class, allogeneic regenerative cell therapy designed to address underlying disc degeneration rather than provide symptomatic relief. Its off-the-shelf design, low immunogenicity, RMAT and Fast Track designations, and FDA-aligned Phase III PIVOT and CONFIRM programs strengthen its development profile. Early safety findings, including a recent favorable DSMB review, are reassuring but remain preliminary.
Discover more about therapies set to grab Major Chronic Lower Back Pain Market Share @ Chronic Lower Back Pain Market Drivers and Barriers
Chronic Lower Back Pain Market Outlook
Chronic Lower Back Pain management is primarily multimodal and function-focused, reflecting its heterogeneous mechanical, degenerative, neuropathic, and psychosocial etiology. Conservative care, including education, exercise, physiotherapy, weight management, and NSAIDs, remains foundational, while duloxetine, muscle relaxants, selected opioids, epidural injections, and surgery are used according to disease severity and treatment response. The market remains largely generic-dominated; however, limited durability, safety concerns, opioid dependence, and the symptomatic nature of existing therapies continue to create substantial unmet need. The pipeline is increasingly focused on non-opioid, regenerative, disease-modifying, and targeted approaches, with late-stage candidates such as SP-102, IDCT, rexlemestrocel-L, SB-01, BRTX-100, and Olastrocel, alongside emerging approaches such as PP353, HYDRAFIL, retatrutide, and novel analgesics. Overall, the launch of first-in-class therapies, improved genetic testing, and rising disease awareness are expected to drive steady growth in the 7MM Chronic Lower Back Pain Therapeutics Market from 2022–2036. The key factors driving the market include the increasing prevalence of CLBP and an aging population, a growing preference for non-opioid and minimally invasive therapies, and advances in treatment modalities and personalized pain management.
Chronic Lower Back Pain Treatment Landscape
Managing CLBP involves a multimodal approach aimed at reducing pain, improving function, and enhancing quality of life. Initial treatment typically includes non-pharmacological interventions alongside non-opioid analgesics such as acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase-2 (COX-2) inhibitors, while long-term use of muscle relaxants is generally discouraged due to limited efficacy and safety concerns. For patients with moderate-to-severe pain who do not achieve adequate relief with first-line therapies, opioid analgesics may be considered under careful medical supervision. Key unmet needs include limited long-term efficacy and the need for durable disease control, heavy reliance on opioids due to limited long-term alternatives, high patient heterogeneity and variable treatment response, and diagnostic uncertainty and imaging–symptom disconnect.
To know more about Chronic Lower Back Pain Companies working in the treatment market, visit @ Chronic Lower Back Pain Market Access and Reimbursement
Scope of the Chronic Lower Back Pain Market Report
Coverage- 7MM
Study Period- 2022-2036
Forecast Period- 2026-2036
Chronic Lower Back Pain Companies- Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, Camurus, Scilex Holding, Mesoblast Limited, AnGes MG, Kolon Life Science, DiscGenics, VERTANICAL, Spine BioPharma, Grünenthal, Tris Pharma, BioRestorative Therapies, Stayble Therapeutics, and others.
Chronic Lower Back Pain Therapies- VER-01 (EXILBY), Oxycodone ER abuse-deterrent (XTAMPZA ER), Buprenorphine Buccal Film (BELBUCA), SEMDEXA (SP-102), Retatrutide (LY3437943), Vicatertide (SB-01), Rebonuputemcel (IDCT), Rexlemestrocel-L (MPC-06-ID), and others.
Chronic Lower Back Pain Market Dynamics: Chronic Lower Back Pain market drivers and market barriers
Chronic Lower Back Pain Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis
Chronic Lower Back Pain Unmet Needs, KOL Views, Reimbursement
Table of Contents
Key Insights
Report Introduction
Executive Summary of Chronic Lower Back Pain (CLBP)
Key Events
Epidemiology and Market Forecast Methodology of Chronic Lower Back Pain (CLBP)
Chronic Lower Back Pain (CLBP) Market Overview at a Glance
Disease Background and Overview of Chronic Lower Back Pain (CLBP)
Epidemiology and Patient Population: 7MM Analysis
Patient Journey
Key Endpoints in CLBP Clinical Trials
Marketed Therapies
Emerging Therapies
Chronic Lower Back Pain (CLBP): 7MM Market Analysis
Unmet Needs Related to Chronic Lower Back Pain (CLBP)
SWOT Analysis of Chronic Lower Back Pain (CLBP)
KOL Views Related to Chronic Lower Back Pain (CLBP)
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Abhishek kumarEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market
